enGene Holdings Inc. Stock price

Equities

ENGN

CA29286M1059

Biotechnology & Medical Research

End-of-day quote Nasdaq 23:00:00 29/02/2024 GMT 5-day change 1st Jan Change
15.47 USD +4.88% Intraday chart for enGene Holdings Inc. +2.79% +67.61%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * - Sales 2025 * - Capitalization 668M 52.71B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 32
Yield 2024 *
-
Yield 2025 *
-
Free-Float 64.41%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.88%
1 week+2.79%
Current month+4.88%
1 month+99.61%
3 months+106.27%
6 months+42.06%
Current year+67.61%
More quotes
1 week
13.26
Extreme 13.26
16.23
1 month
7.31
Extreme 7.3065
17.13
Current year
7.10
Extreme 7.1
17.13
1 year
6.69
Extreme 6.69
47.17
3 years
6.69
Extreme 6.69
47.17
5 years
6.69
Extreme 6.69
47.17
10 years
6.69
Extreme 6.69
47.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 07/08/23
Founder 52 23/04/23
President - 10-31
Members of the board TitleAgeSince
Director/Board Member 64 12-17
Chief Executive Officer 54 07/08/23
Director/Board Member 55 07/08/23
More insiders
Date Price Change Volume
01/03/24 15.47 +4.88% 63,218
29/02/24 14.75 -7.17% 49,064
28/02/24 15.89 +3.79% 66,295
27/02/24 15.31 -1.80% 57,278
26/02/24 15.59 +3.59% 83,900

End-of-day quote Nasdaq, March 29, 2024

More quotes
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
15.47 USD
Average target price
31 USD
Spread / Average Target
+100.39%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock enGene Holdings Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW